secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2024-01-24T23:59:59+00:00
Accession:  0001193125-24-013587
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics gets FDA approval for ZYNRELEF indication expansion covering 13M annual procedures
--------------------------------------------------------------------------------

- FDA approved supplemental NDA for ZYNRELEF to include soft tissue and orthopedic surgical procedures, including foot and ankle.
- Expanded indication now covers an estimated 13 million procedures annually, an 86% increase over prior indicated procedures.
- No unique safety issues identified in new clinical trials for cesarean section, spinal surgery, augmentation mammoplasty, and total shoulder arthroplasty.
- CEO Craig Collard highlights label expansion, CrossLink partnership, and potential VAN approval as transformative for ZYNRELEF.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000119312524013587/0001193125-24-013587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000119312524013587/d626508d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-013587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer